FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma By Ogkologos - May 20, 2026 185 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms November 1, 2019 Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... October 1, 2021 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 Cancer in My Community: Providing Supportive Care in Serbia October 14, 2021 Load more HOT NEWS Opinion: ‘We can’t afford to stop now’ Adding Upfront SRS to CNS-penetrant TKI Improves Time-to-CNS Progression and Local... DNA from Ancient Viruses Helps Many Cancers Grow Getting Better Sleep When You Have Cancer-Related Insomnia: An Expert Q&A
